Elicio Therapeutics, Inc.
Data quality: 83%
ELTX
NASDAQ
Manufacturing
Chemicals
$11.78
▲
$0.05
(0.43%)
6 months return
—
Momentum
Neutral
ROE
-1400.74%
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-1400.74%
Below sector avg (-54.68%)
ROIC-144.02%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
2.55
Above sector avg (0.30)
Current Ratio3.29
Interest Coverage-33.29
Valuation
PE (TTM|NTM)
-4.78 | -6.66
Below sector avg (-1.50)
P/B Ratio49.56
EV/EBITDAN/A
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Debt/Equity of 2.55 — high leverage
Negative free cash flow of -36.97 M
Price History
Financial Trends
Analyst Price Target
3 analysts
Buy
+55.6%
upside to target
Current
$11.78
Consensus Target
$18.33
$17.00
Low
$20.00
High
Forecast
Forward P/E
-6.66
Forward EPS
-$1.77
Est. Revenue
0.0
Earnings Surprises
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -$0.50
·
Rev Est: 0.0
| Q12025 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|
| Reported | -$0.87 | -$0.66 | -$0.60 | -$0.49 | — | — |
| Estimate | -$0.83 | -$0.69 | -$0.48 | -$0.45 | -$0.50 | -$0.48 |
| Surprise | -4.82% | +3.65% | -25.00% | -10.11% | — | — |
Growth
Rev 5Y: N/A · Earnings 1Y: N/A
Growth
Rev 5Y: N/A · Earnings 1Y: N/A| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
Profitability
ROE: -1400.74% · Net Margin: N/A
Profitability
ROE: -1400.74% · Net Margin: N/A| Revenue (TTM) | N/A | Net Income (TTM) | -39.57 M |
| ROE | -1400.74% | ROA | -136.90% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -36.97 M |
| ROIC | -144.02% | FCF Growth (3Y) | N/A |
Safety
D/E: 2.55 · Current: 3.29
Safety
D/E: 2.55 · Current: 3.29| Debt / Equity | 2.55 | Current Ratio | 3.29 |
| Interest Coverage | -33.29 | Asset Turnover | N/A |
| Working Capital | 14.95 M | Tangible Book Value | 3.82 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: -4.78 · EV/EBITDA: N/A
Valuation
P/E: -4.78 · EV/EBITDA: N/A| P/E Ratio | -4.78 | Forward P/E | -6.66 |
| P/B Ratio | 49.56 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -19.55% | ||
| Market Cap | 189.11 M | Enterprise Value | 178.22 M |
Per Share
EPS: -2.58 · FCF/Share: -2.01
Per Share
EPS: -2.58 · FCF/Share: -2.01| EPS (Diluted TTM) | -2.58 | Revenue / Share | N/A |
| FCF / Share | -2.01 | OCF / Share | -2.01 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: 93.42% · CapEx/Rev: N/A
Efficiency
FCF Conv: 93.42% · CapEx/Rev: N/A| CapEx / Revenue | N/A | FCF Conversion | 93.42% |
| SBC-Adj. FCF | -39.21 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | 2.30 M | 28.31 M |
| Net Income | -39.57 M | -51.90 M | -35.20 M | -38.81 M | -54.57 M |
| EPS (Diluted) | -2.58 | -4.25 | -6.96 | -1.29 | -1.93 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -37.71 M | -44.99 M | -35.75 M | -39.62 M | -39.31 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 24.90 M | 33.66 M | 23.85 M | 18.10 M | 48.70 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | 1.13 M | 455,000.0 | 1.06 M | 805,000.0 | -1.85 M |
| Income Tax | 0.0 | 0.0 | 0.0 | 11,000.0 | 0.0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 25.86 M | 28.18 M | 27.15 M | 52.79 M | 96.51 M |
| Total Liabilities | 24.23 M | 39.49 M | 15.77 M | 9.02 M | 15.01 M |
| Shareholders' Equity | 1.64 M | -11.31 M | 11.37 M | 43.77 M | 81.51 M |
| Total Debt | 10.00 M | — | — | — | 0.0 |
| Cash & Equivalents | 18.56 M | 17.62 M | 12.89 M | 50.49 M | 88.76 M |
| Current Assets | 19.31 M | 20.69 M | 16.35 M | 51.43 M | 91.25 M |
| Current Liabilities | 8.11 M | 11.52 M | 9.77 M | 6.37 M | 11.30 M |
Peer Comparison
vs Manufacturing sector median (1605 peers)
Compared with similar companies in Manufacturing
Peer Comparison
vs Manufacturing sector median (1605 peers) Compared with similar companies in Manufacturing| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -4.8 | -1.5 |
| P/B | 49.6 | 1.6 |
| ROE % | -1400.7 | -54.7 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.7 |
| D/E | 2.6 | 0.3 |
{"event":"ticker_viewed","properties":{"ticker":"ELTX","listing_kind":"stock","pathname":"/stocks/eltx","exchange":"NASDAQ","country":"US"}}